A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma

We investigated 2-weekly intravenous irinotecan combined with oral capecitabine in patients with advanced gastroesophageal adenocarcinoma. In phase I, doses were escalated in chemotherapy naïve or pretreated patients to establish maximum tolerated doses (MTD). In phase II, patients were treated at M...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Burge, M E, Smith, D, Topham, C, Jackson, D P, Anthoney, D A, Halstead, F, Seymour, M T
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2006
Gaiak:
Clinical Study
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361406/
https://ncbi.nlm.nih.gov/pubmed/16622464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603084
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak